PFM Health Sciences’s Glaukos GKOS Stock Holding History

PFM Health Sciences’s Portfolio GKOS Stock Details GKOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-215,685	Closed	-$23.2M	–	104
2026 Q1	$23.2M	Buy	215,685 +14,009	+7%	+$1.58M	2.12%	12
2025 Q4	$22.8M	Buy	+201,676	New	+$19.3M	2.27%	11

Other funds holding GKOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

PFM Health Sciences's GKOS Position: Q2 2026 in Review

PFM Health Sciences sold out of Glaukos (GKOS) in Q2 2026, closing a stake of 215,685 shares — an estimated $23.2M sold.

PFM Health Sciences first reported a position in GKOS in Q4 2025 and held it in 2 quarters. The position peaked at $23.2M in Q1 2026. 366 funds tracked by Wall St. Rank hold GKOS as of Q2 2026.

PFM Health Sciences reported no remaining Glaukos position as of Q2 2026 after selling out during the quarter.
PFM Health Sciences sold 215,685 Glaukos shares in Q2 2026, an estimated $23.2M.
PFM Health Sciences first reported a position in Glaukos in Q4 2025 and held it in 2 quarters.
PFM Health Sciences's Glaukos position peaked at $23.2M in Q1 2026.
366 funds tracked by Wall St. Rank held Glaukos as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.